| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Vitamin D/Vitamin D receptor
Target: 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 targets the vitamin D/vitamin D receptor (VDR) pathway. It is a derivative of 25-hydroxyvitamin D3 and interacts with vitamin D binding proteins and the vitamin D receptor. The compound may function as a metabolism inhibitor by interfering with vitamin D activation pathways. |
|---|---|
| ln Vitro |
3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 is a 25-hydroxyvitamin D3 derivative[1].
In Vitro Activity: 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 is a 25-hydroxyvitamin D3 derivative. It is used as a research tool for studying vitamin D metabolism and receptor interactions. The compound contains a highly reactive amine group that can be coupled to a sepharose matrix for affinity purification of vitamin D binding protein. Detailed in vitro activity data are available from the primary literature. |
| ln Vivo |
In Vivo Activity: 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 has been studied for potential applications in vitamin D-related research. Detailed in vivo efficacy data are limited in publicly available sources. The compound is primarily used as a research tool for affinity purification and vitamin D metabolism studies.
|
| Enzyme Assay |
In Vitro Enzyme/Receptor Binding Protocol: Vitamin D receptor binding assays typically use recombinant VDR protein or cell extracts. Radioligand binding with [3H]1,25(OH)2D3 is performed with varying concentrations of 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 to determine relative binding affinity. The compound's amine group enables coupling to sepharose matrix for affinity purification of vitamin D binding protein.
|
| Cell Assay |
In Vitro Cell-Based Assay Protocol: Cells expressing VDR or vitamin D binding protein are treated with 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 at various concentrations. VDR activation and downstream gene expression are measured using reporter gene assays or qPCR. Affinity purification experiments may be performed using sepharose-coupled compound.
|
| Animal Protocol |
In Vivo Animal Assay Protocol: Animal models of vitamin D-related diseases may be used to study 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3. The compound is administered via appropriate routes, and calcium, phosphate, and vitamin D metabolite levels are measured. Detailed protocols are available from the primary literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetics: 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 has molecular formula C30H51NO2 and molecular weight 457.73. It is a Vitamin D3 analogue with a highly reactive amine group. As a vitamin D analog, it is expected to have similar absorption and distribution properties to native vitamin D compounds.
|
| Toxicity/Toxicokinetics |
Toxicity: No detailed toxicity data are publicly available for 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3. As a vitamin D analog, it may cause hypercalcemia at high doses. Standard toxicological evaluation would be required for therapeutic development. The compound is for research use only.
|
| References | |
| Additional Infomation |
3'-O-aminopropyl-25-hydroxyvitamin D3 is a type of vitamin D.
Additional Information: 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 has CAS number 163018-26-6. It is also known as 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3. The compound is a Vitamin D3 analogue and 25-hydroxyvitamin D3 derivative. It contains a highly reactive amine group that can be coupled to a sepharose matrix for affinity purification of vitamin D binding protein. For research use only, not for human therapy. |
| Molecular Formula |
C30H51NO2
|
|---|---|
| Molecular Weight |
457.7314
|
| Exact Mass |
457.392
|
| CAS # |
163018-26-6
|
| Related CAS # |
27460-33-9 (Chol-5-en-24-al-3β-ol); 29261-12-9 (25,26-Dihydroxyvitamin D3)
|
| PubChem CID |
12020395
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.807
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
33
|
| Complexity |
721
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)OCCCN)C
|
| InChi Key |
RAIPMHBURQASRR-BAUWAPLESA-N
|
| InChi Code |
InChI=1S/C30H51NO2/c1-22-11-14-26(33-20-8-19-31)21-25(22)13-12-24-10-7-18-30(5)27(15-16-28(24)30)23(2)9-6-17-29(3,4)32/h12-13,23,26-28,32H,1,6-11,14-21,31H2,2-5H3/b24-12+,25-13-/t23-,26+,27-,28+,30-/m1/s1
|
| Chemical Name |
(6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-(3-aminopropoxy)-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptan-2-ol
|
| Synonyms |
3-O-(2-Aminoethyl)-25-hydroxyvitamin D3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~218.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1847 mL | 10.9235 mL | 21.8469 mL | |
| 5 mM | 0.4369 mL | 2.1847 mL | 4.3694 mL | |
| 10 mM | 0.2185 mL | 1.0923 mL | 2.1847 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA